{"nctId":"NCT02016716","briefTitle":"A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis","startDateStruct":{"date":"2013-12-03","type":"ACTUAL"},"conditions":["Postmenopausal Osteoporosis"],"count":294,"armGroups":[{"label":"Romosozumab 90 mg/mL","type":"EXPERIMENTAL","interventionNames":["Drug: Romosozumab 90 mg/mL"]},{"label":"Placebo 90 mg/mL","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo 90 mg/mL"]},{"label":"Romosozumab 70 mg/mL","type":"EXPERIMENTAL","interventionNames":["Drug: Romosozumab 70 mg/mL"]},{"label":"Placebo 70 mg/mL","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo 70 mg/mL"]}],"interventions":[{"name":"Romosozumab 90 mg/mL","otherNames":["AMG 785","EVENITY™"]},{"name":"Placebo 90 mg/mL","otherNames":[]},{"name":"Romosozumab 70 mg/mL","otherNames":["AMG 785","EVENITY™"]},{"name":"Placebo 70 mg/mL","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPostmenopausal women with osteoporosis at high risk for fracture defined as\n\n* BMD T-score ≤ -2.50 at the lumbar spine, total hip, or femoral neck AND\n* a history of fragility fracture or at least 2 other risk factors\n\nExclusion Criteria:\n\n* BMD T score \\< -3.50 at the total hip or femoral neck.\n* History of hip fracture.\n* History of metabolic or bone disease (except osteoporosis).\n* Use of agents affecting bone metabolism.\n* Vitamin D insufficiency.\n* History of solid organ or bone marrow transplants.\n* Hyper- or hypocalcemia.\n* Hyper- or hypothyroidism.\n* Hyper- or hypoparathyroidism.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"55 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine","description":"Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"9.6","spread":null},{"groupId":"OG002","value":"9.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Hip BMD","description":"Total hip BMD was measured using DXA. The analysis was based on an ANCOVA model adjusted for treatment and baseline total hip BMD T-score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":null},{"groupId":"OG001","value":"3.9","spread":null},{"groupId":"OG002","value":"3.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Femoral Neck BMD","description":"Femoral neck BMD was measured using DXA. The analysis was based on an ANCOVA model adjusted for treatment and baseline femoral neck BMD T-score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":null},{"groupId":"OG001","value":"3.1","spread":null},{"groupId":"OG002","value":"2.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in N-Terminal Propeptide Type 1 Procollagen (P1NP)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.000","spread":null},{"groupId":"OG001","value":"96.296","spread":null},{"groupId":"OG002","value":"97.435","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.601","spread":null},{"groupId":"OG001","value":"23.960","spread":null},{"groupId":"OG002","value":"16.216","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.500","spread":null},{"groupId":"OG001","value":"-2.885","spread":null},{"groupId":"OG002","value":"-3.604","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Serum C-Telopeptide (CTX)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.282","spread":null},{"groupId":"OG001","value":"-23.158","spread":null},{"groupId":"OG002","value":"-21.456","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.687","spread":null},{"groupId":"OG001","value":"-11.219","spread":null},{"groupId":"OG002","value":"-5.473","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.120","spread":null},{"groupId":"OG001","value":"-25.780","spread":null},{"groupId":"OG002","value":"-17.305","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":26},"commonTop":["Nasopharyngitis","Asthenia","Injection site pain","Injection site erythema","Urinary tract infection"]}}}